Stock comparison
Genmab A/S
Ironwood Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
IRWD
Ironwood Pharmaceuticals
Market cap
$645.28M
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | IRWD | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 47D | GMAB |
| Benjamin Graham | 64C | 25F | GMAB |
| Philip Fisher | 48D | 41D | GMAB |
| Peter Lynch | 25F | 26F | IRWD |
| Joel Greenblatt | 76B | 69B | GMAB |
| Charlie Munger | 68C | 68D | Tie |
| Terry Smith | 71C | 66C | GMAB |
Side-by-side metrics
| Metric | GMAB | IRWD |
|---|---|---|
| Market cap | $16.5B | $645.28M |
| P/E (TTM) | 6.2x | 4.5x |
| EV/EBIT | 12.0x | 9.0x |
| ROIC (TTM) | 43.78% | 43.86% |
| Gross margin | 93.88% | 99.75% |
| Net margin | 18.23% | 41.76% |
| Revenue CAGR 5y | -18.45% | -8.02% |
| EPS CAGR 5y | -23.48% | -53.69% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $645.28M+96%
- EPS CAGR 5y-23.48%vs -53.69%+56%
IRWD leads on
- Debt / Equity-vs 0.1x+103%
- Revenue CAGR 5y-8.02%vs -18.45%+57%
- Net margin41.76%vs 18.23%+56%
- P/E (TTM)4.5xvs 6.2x+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.